AxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET

Company Participants

Adanna Alexander - IR Consultant

Karen Zaderej - Chairman, CEO and President

Pete Mariani - EVP and CFO

Conference Call Participants

Michael Sarcone - Jefferies

Caitlin Cronin - Canaccord Genuity

Dave Turkaly - JMP Securities

Operator

Greetings. Welcome to the AxoGen Reports Third Quarter 2023 Financial Results. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the conference over to Adanna Alexander, Investor Relations Consultant. Adanna, you may now begin.

Adanna Alexander

Thanks Rob. Good morning, everyone.

Joining me on today's call is Karen Zaderej, AxoGen's Chairman, Chief Executive Officer and President; and Pete Mariani, Executive Vice President and Chief Financial Officer. Karen will discuss the quarter and our outlook for the year, and Pete will provide an analysis of our financial performance and guidance, followed by a question-and-answer session.

Today's call is being broadcast live via webcast, which is available on the Investors section of the AxoGen's website. Following the end of the live call, a replay will be available in the Investors section of the company's website at www.axogeninc.com.

Before we get started, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements including our expectations regarding our ability to expand our footprint and expand core accounts, anticipated growth for revenue categories, penetration of core accounts, marketing opportunities with nerve applications associated with emergent trauma, breast, OMF, and surgical treatment of pain and new products. Our expectations regarding the timing of a launch for Avive Plus, our expectations regarding our ability to make a rolling biologics license application submission for advanced nerve grafts, and the timing of the BLA submission for approval. Our belief that our balance sheet will continue to be sufficient to bridge through to cash flow breakeven and longer-term profitability. Our expectation is that we will continue trending towards cash flow breakeven, and our belief that trends towards operating leverage will allow us to maintain a strong balance sheet position and provide ample support as we work towards profitability. Our 2023 financial guidance, including revenue range and gross margin, optimism associated with the adoption of our new products, key strategic pillars, and our balance sheet.

Forward-looking statements are based on current beliefs and assumptions and are not guarantees of future performance and are subject to risks and uncertainties, including, not without limitation, the risks and uncertainties reflected in the company's annual and periodic reports, such as hospital staffing issues, regulatory process and approvals, surgeon and product adoption, and market awareness of our products. The forward-looking statements are representative only as of the date they are made and accept as required by applicable law. We assume no responsibility to publicly update or revive any forward-looking statements.